|Friday, 6 July 2012, 15:00 HKT|
Source: marcus evans Summits
|Prof Dr Geerd Weyer of ICRC-Weyer, a sponsor company at the marcus evans Evolution Summit 2012, on why drug development requires flexibility in the trial design. |
London, July 6, 2012 - (ACN Newswire) - Innovation in drug development requires flexibility in the clinical trial design, not merely standardisation, according to Prof Dr Geerd Weyer, Managing Director, ICRC-Weyer. Every trial is unique and must be designed and treated as such, he adds.
From a contract research organisation attending the upcoming marcus evans Evolution Summit 2012, in Munich, Germany, 14 - 16 October, Prof Dr Weyer talks about clinical trials and how adaptability can accelerate clinical development.
- What would accelerate drug development and delivery/time to market?
In the last few years, many large pharmaceutical companies have been contracting out clinical development services to single, globally acting service providers. They tend to believe that the globalisation of drug development gives them strength and allows them to avoid friction in processes that they would have if they had multiple interfaces and vendors. They believe that this will help them save time and effort, but I consider this to be a one-sided view. Using the services of a niche or specialist provider could help them accelerate clinical development.
- Would this limit innovation in any way?
When it comes to innovation, a service provider that can be flexible should be preferred. Smaller organisations are able to bring in study-specific solutions, while larger organisations can bring in productivity and efficiency as they are able to streamline and standardise services.
There is a dichotomy between efficiency and productivity on the one side, and innovation on the other. However, standardisation does not always work. Processes must be adapted to each study. Clinical development is a process where innovation and flexibility are needed, at least as much as standardisation.
- What is unique about your approach and philosophy?
We are well aware of the dichotomy I mentioned before, but our philosophy has always been one of cooperation and partnership with clients and other service providers; bringing together our own strengths as a flexible specialist with the strengths of other providers.
Our philosophy is also reflected in the way we integrate services across departments. Likewise, our data systems are optimised to seamlessly integrate data from various sources, internal or external.
- What is key to clinical research and trial success?
The key is to have the right data in high quality when needed. This can be achieved by recognising the value that a specialist provider in that respective area can bring, and by not totally relying on standard solutions.
There is no single way for succeeding in clinical development. Every trial is unique and must be designed and treated as such.
About the Evolution Summit 2012
This unique forum will take place at the Hotel Four Seasons Kempinski, Munich, Germany, 14 - 16 October 2012. Offering much more than any conference, seminar or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. For more information please send an email to firstname.lastname@example.org or visit the event website at www.evolution-summit.com.
marcus evans group - life sciences / pharma sector portal: http://tiny.cc/1OCf2b
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
- LinkedIn: www.linkedin.com/groups?mostPopular=&gid=3529112
- YouTube: www.slideshare.net/MarcusEvansPharma
- Twitter: www.twitter.com/meSummitsPharma
- SlideShare: www.youtube.com/user/MarcusEvansPharma
Please note that the Summit is a closed business event and the number of participants strictly limited.
Located in Berlin, Germany, ICRC-Weyer is an all-Phase CRO with almost 20 years experience. The company provides its services for the pharmaceutical and nutrition industries. These center on specialist solutions for independent medical review, expert consulting and pharmacovigilance, which are integrated with the data management, statistical analysis and medical and regulatory writing packages being offered. www.icrc-weyer.com.
About marcus evans Summits
marcus evans Summits are high level business forums for the world's leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings. For more information, please visit www.marcusevans.com.
- Twitter: www.twitter.com/meSummitsGlobal
- YouTube: www.youtube.com/user/MarcusEvansGroup
- SlideShare: www.slideshare.net/MarcusEvansSummits
Press Manager, marcus evans, Summits Division
Tel: + 357 22 849 313
July 6, 2012
Source: marcus evans Summits
Topic: Research / Industry Report
Sectors: Financial General, Business General
From the Asia Corporate News Network
Copyright © 2013 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|marcus evans Summits|
|Mar 18, 2013|
Japanese Investments Summit 2013: Mapping Out the Next Step for Japanese Investors|
|Dec 3, 2012|
Designing the Optimal Family Governance Structure|
|Nov 29, 2012|
Collaboration is the Name of the Game in the Medical Device R&D Industry|
|Nov 21, 2012|
Manufacturing the Appropriate Medical Devices for the Right Market|
|Nov 16, 2012|
Switching from an Information to a Business Technology|
|Nov 14, 2012|
Why Investors Should Focus on Dynamic Asset Allocation|
|Nov 14, 2012|
Reinvesting in Infrastructure for Reliable Transmission and Distribution|
|Nov 12, 2012|
Crunching Down on Tax Credits to Know Your Tax Incentives|
|Nov 12, 2012|
Evaluating the True Value of Corporate Benefits Programs|
|Nov 7, 2012|
Upfront Communication Makes for Better Medical Device Manufacturing|
|More news >>|